Show simple item record

dc.contributor.authorBrandish, P.
dc.contributor.authorAnderson, K.
dc.contributor.authorBaltus, G.
dc.contributor.authorBai, C.
dc.contributor.authorBungard, C.
dc.contributor.authorBunting, P.
dc.contributor.authorByford, A.
dc.contributor.authorChiu, C.
dc.contributor.authorCicmil, M.
dc.contributor.authorCorcoran, H.
dc.contributor.authorEuler, D.
dc.contributor.authorFisher, J.
dc.contributor.authorGambone, C.
dc.contributor.authorHasbun-Manning, M.
dc.contributor.authorKuklin, N.
dc.contributor.authorLandis, E.
dc.contributor.authorLifsted, T.
dc.contributor.authorMcElwee-Witmer, S.
dc.contributor.authorMcIntosh, I.
dc.contributor.authorMeissner, R.
dc.contributor.authorMiao, J.
dc.contributor.authorMitchell, H.
dc.contributor.authorMusselman, A.
dc.contributor.authorSchmidt, A.
dc.contributor.authorShin, J.
dc.contributor.authorSzczerba, P.
dc.contributor.authorThompson, C.
dc.contributor.authorTribouley, C.
dc.contributor.authorVogel, R.
dc.contributor.authorWarrier, Sudha
dc.contributor.authorHershey, J.
dc.identifier.citationBrandish, P. and Anderson, K. and Baltus, G. and Bai, C. and Bungard, C. and Bunting, P. and Byford, A. et al. 2014. The preclinical efficacy, selectivity and pharmacologic profile of MK-5932, an insulin-sparing selective glucocorticoid receptor modulator. European Journal of Pharmacology. 724 (1): pp. 102-111.

Glucocorticoids are used widely in the treatment of inflammatory diseases, but use is accompanied by a significant burden of adverse effects. It has been hypothesized that gene- and cell-specific regulation of the glucocorticoid receptor by small molecule ligands could be translated into a therapeutic with an improved risk-benefit profile. MK-5932 is a highly selective glucocorticoid receptor modulator that is anti-inflammatory in vivo with an improved profile on glucose metabolism: Bungard et al. (2011). Bioorg. Med. Chem. 19, 7374-7386. Here we describe the full biological profile of MK-5932. Cytokine production following lipopolysaccharide (LPS) challenge was blocked by MK-5932 in both rat and human whole blood. Oral administration reduced inflammatory cytokine levels in the serum of rats challenged with LPS. MK-5932 was anti-inflammatory in a rat contact dermatitis model, but was differentiated from 6-methylprednisolone by a lack of elevation of fasting insulin or glucose levels after 7 days of dosing, even at high exposure levels. In fact, animals in the vehicle group were consistently hyperglycemic at the end of the study, and MK-5932 normalized glucose levels in a dose-dependent manner. MK-5932 was also anti-inflammatory in the rat collagen-induced arthritis and adjuvant-induced arthritis models. In healthy dogs, oral administration of MK-5932 exerted acute pharmacodynamic effects with potency comparable to prednisone, but with important differences on neutrophil counts, again suggestive of a dissociated profile. Important gaps in our understanding of mechanism of action remain, but MK-5932 will be a useful tool in dissecting the mechanisms of glucose dysregulation by therapeutic glucocortiocids. © 2013 Elsevier B.V.

dc.titleThe preclinical efficacy, selectivity and pharmacologic profile of MK-5932, an insulin-sparing selective glucocorticoid receptor modulator
dc.typeJournal Article
dcterms.source.titleEuropean Journal of Pharmacology
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusFulltext not available

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record